Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.
Alessio CortelliniA LeonettiA CatinoP PizzutilloB RicciutiA De GiglioR ChiariP BordiD SantiniR GiustiM De TursiD BroccoF ZorattoF RastelliF CitarellaM RussanoM FilettiP MarchettiR BerardiM TorniaiD CortinovisE SalaC MaggioniA FolladorM MacerelliO NigroA TuziD IaconoM R MigliorinoG BannaG PorzioK CannitaM G FerraraE BriaD GalettaC FicorellaM TiseoPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)
Our study confirmed that in clinical practice, in case of "non-druggable" disease progression, maintaining osimertinib beyond progression (with adjunctive LATs) is an effective option.